Real-World Evidence Study Emulates KEYNOTE-042: Pembrolizumab vs Chemotherapy in Advanced NSCLC — What Clinicians Need to Know

References

1. 1.Brigham and Women's Hospital. (2024). Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07485179
2. 2.Hernán, M. A., & Robins, J. M. (2020). Using big data to emulate a target trial when a randomized trial is not available. American Journal of Epidemiology, 189(6), 435-442. https://doi.org/10.1093/aje/kwaa084
3. 3.Mok, T. S., Wu, Y. L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., Kubota, K., Lubiniecki, G. M., Zhang, J., Kush, D., & Lopes, G. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet, 393(10183), 1819-1830. https://doi.org/10.1016/S0140-6736(18)32409-7
4. 4.Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., & Peters, S. (2018). Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 29(Supplement 4), iv192-iv237. https://doi.org/10.1093/annonc/mdy275
5. 5.Sherman, R. E., Anderson, S. A., Dal Pan, G. J., Gray, G. W., Gross, T., Hunter, N. L., LaVange, L., Marinac-Dabic, D., Marks, P. W., Robb, M. A., Shuren, J., Temple, R., Woodcock, J., Yue, L. Q., & Califf, R. M. (2016). Real-world evidence — what is it and what can it tell us? New England Journal of Medicine, 375(23), 2293-2297. https://doi.org/10.1056/NEJMsb1609216